IsoRay Inc. announced that the FDA has cleared liquid cesium for use in IsoRay's GliaSite radiation therapy system, a balloon catheter device used to treat certain brain cancers. IsoRay's Cesium-131 in liquid form, used with the GliaSite radiation therapy system, as well as sutured seeds and seeded mesh products, each provide physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of brain tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy brain and lung tissue as well as critical structures compared to other alternative treatments.

IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life. IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form and now in liquid for brachytherapy in approximately 20 years.

Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation). IsoRay's products are currently used for the treatment of brain, head and neck, lung, prostate and gynecological cancers.